Club of Amsterdam, Future, Think Tank ..

Club of Amsterdam Journal
Free Subscription
click here

























































































































keyword search
Books about the future of Life Sciences

. Books about the future of Life Sciences

Drugs-From Discovery to Approval
by Rick Ng

Statistics show that out of five thousand compounds with initial promise, five will go into human clinical trials, and only one will become an approved drug. This tiny fraction illustrates the huge complexities involved in bringing a drug to market, a process that brings together scientific research, medical ethics, business, and various regulatory agencies. Drugs From Discovery to Approval presents a clear, step-by-step overview of the entire process. Using simple language, this comprehensive guide introduces basic concepts, then moves on to discuss disease target selection and the discovery processes for both small and large molecule drugs. Subsequent chapters explain preclinical studies, clinical trials, regulatory issues, good manufacturing practices (GMPs), and perspectives on the future. Coverage also includes: A helpful listing of current FDA and European guidelines A special section on regulatory authorities and processes in Japan and China Rich illustrations throughout, including more than ninety figures and tables Useful appendices on the history of drug discovery and development Representative examples of drug mechanisms in action Written for professionals in the pharmaceutical industry, and readily accessible for students of pharmacy or medicine and others interested in drug discovery, Drugs From Discovery to Approval represents a practical and approachable reference on this important process.

Big Pharma : How Modern Medicine is Damaging Your Health and What You Can Do About It

by Jacky Law

The drug business is the most profitable in all of capitalism, journalist Law notes in this scattershot indictment of the pharmaceutical industry, but what do consumers get for the money shoveled into it? A dwindling stream of exorbitantly expensive new drugs, she contends, most of them "me-too" competitors, patent-prolonging reformulations of existing products or marginally effective nostrums for diffuse complaints; vast marketing budgets to cajole consumers into demanding-and doctors into prescribing-unnecessary medications; biased scientific studies and corrupted or intimidated researchers; a regulatory system lobbied and suborned into allowing unsafe and ineffective drugs on the market; and a society that automatically pops a pill for every discontent, real or imagined. Law offers a comprehensive, if disorganized, rehash of a now familiar but still timely portrait of drug companies' perfidy and greed, studded with case studies of firestorms like the Vioxx scandal and the controversy over the possibly deadly side-effects of anti-depressants. She's on shakier ground when she dilates her case into a brief against conventional medicine and in favor of a murky "holistic" regimen of "complementary"-i.e. alternative-therapies that harmonize with "the body's natural intelligence" and exploit the "untapped healing power" of the placebo effect. Law's flirtations with fringe conceits weaken an otherwise serviceable science-based critique of the drug industry.

Liberation Biology: The Scientific and Moral Case for the Biotech Revolution
by Ronald Bailey

Ronald Bailey examines the scientific and ethical controversies surrounding everything from stem cell research to therapeutic cloning to longer life spans to genetically modified food. Bailey writes, "The benefits of biotechnology are well known – the cure of diseases and disabilities for millions of sufferers; the production of more nutritious food with less damage to the natural environment; the enhancement of human physical and intellectual capacities - and all can be easily foreseen. It is the alleged dangers of biotechnology that are, in fact, vague, ill defined, and nebulous."

Bailey, whose work was featured in The Best American Science and Nature Writing 2004, makes the case that science can, and will, help us live longer, healthier, and happier lives, without creating human clones or designer plagues. Liberation Biology dispels many myths spread by a small faction that hopes to control medical and scientific research (why we won't be seeing a cloned, half-sheep/half-human creature, for example); demonstrates why scientists and doctors, not politicians, should confront the uncertainties that come with biotechnology in the same way they confronted uncertainties about the ethics of X-rays, birth control pills, bypass surgeries, and in vitro fertilization when they were first used; and why patients and families should ultimately have the freedom of choice to embrace stem cell and biotech benefits or reject them for personal reasons.

Human Identity and Bioethics
by David DeGrazia

When philosophers address personal identity, they usually explore numerical identity. When non-philosophers address personal identity, they often have in mind narrative identity. This book develops accounts of both senses of identity, arguing that both are normatively important, and is unique in its exploration of a wide range of issues in bioethics through the lens of identity. Defending a biological view of our numerical identity and a framework for understanding narrative identity, David DeGrazia investigates various issues for which considerations of identity prove critical.

Welcome to the Genome : A User's Guide to the Genetic Past, Present, and Future
by Rob DeSalle, Michael Yudell

Welcome to the genome, the miraculous blueprint of your DNA, coiled tight as a spring in the nucleus of each cell of your body. If unwound, the DNA from just one cell, while only a molecule in width, would stretch six feet in length! The information stored in its double helix structure - three billion bits worth - could fill 142 Manhattan phone books.

Yet far more amazing than these facts is the impact the study of genomics has had on so many areas of our lives. From the promise of personalized medicine and gene therapy to disputes over the safety of genetically modified (GM) foods, there is little doubt we are in the midst of the Genomic Revolution. Now how do we make sense of it all?

Welcome to the Genome takes you right into the thick of today's most cutting-edge science and its far-reaching implications. Authors Rob DeSalle, who curated the highly successful Genomics Revolution exhibit at the American Museum of Natural History in New York, and Michael Yudell, Assistant Professor of Public Health at Drexel University, have written a book which clearly explains the ongoing saga of our attempts to understand the mystery of biology's Rosetta Stone and use its code to better our lives.

This reader-friendly book employs an understandable style and eye-popping full-color illustrations to provide real insights into the complex science involved. It delves into the past discoveries that led to the sequencing of the human genome; it presents the challenges facing today's scientists and society and culture in general; and it considers the future possibilities of the developing genome era. Social issues, particularly questions of ethics, receive special attention, covering an important area too often overshadowed by science and technology.

If the genome really is the book of life, then we have only just opened to the first of its many pages. Those who triumphantly claim DNA is destiny may have spoken too soon; it is far more likely today's discoveries will lead to insights yet to be imagined. A stirring and informative introduction to a scientific epic still unfolding, Welcome to the Genome is an essential guide for understanding - and participating in - the incredible explorations, discussions, and realizations of the Genomic Revolution.

The Biotech Investor's Bible
by George Wolff

A one-stop source for investing in biotech-with detailed coverage of the science, the business, the players, and the strategies for one of today's most promising (and volatile) industries.

To invest in biotech is to invest in the future, and as such, investors need to learn the nuances of the science they're putting their money on. The core asset of biotech companies is knowledge, and sound investment decisions are impossible without an understanding of this complex science. That's where The Biotech Investor's Bible fits in. This much-needed, one-of-a-kind resource simplifies the complex science surrounding the business of biotech and clarifies subtle distinctions within the context of their financial repercussions. The book explains the basics of genetics, patents, and therapies; and teaches investors how to value biotech companies and their state-of-the art products and technology. The Biotech Investor's Bible offers an informative summary of the relatively short history of the industry and provides a comprehensive review of various industry sectors.

George Wolff (St. Pete Beach, FL) is a successful consultant advising clients who are investing in biotech stocks. He has assessed well over 150 biotech companies and has issued a number of valuable white papers that have charted the success of the hottest biotech companies.

The Biotech Age: The Business of Biotech and How to Profit From
by Richard L. Oliver

A look at the forefront of an industry revolution

"I've been deep inside the biotech industry since its infancy. This book provides fresh insights about how it started, what drives it, and most importantly, where it's going." - Scott W. Morrison, partner, Ernst & Young LL

Richard W. Oliver predicted the onset of a new era with The Coming Biotech Age. Now that age is here--and companies are reaping the benefits of this incredible new revolution. As biotech companies become the new economic engines of growth and innovation, businesses must have access to the latest developments of this area of research.

In a special revised edition, now titled The Biotech Age, Oliver has created the first practical guide to this fascinating realm of scientific development. With updated information on the latest research, examples of biotech breakthroughs, and a close examination of current biotech issues such as cloning and stem cell research, The Biotech Age presents an accessible overview of the business of biotechnology and its vast implications and opportunities for all types of industries.

This is a topic no one can afford to miss - especially future-minded executives and investors in cutting-edge technologies.

Building Biotechnology: Starting, Managing, And Understanding Biotechnology Companies
by Yali Friedman

Building Biotechnology - Starting, managing, and understanding biotechnology companies is a comprehensive resource on commercializing biotechnology. The primary audience of 'Building Biotechnology' is business professionals and entrepreneurial scientists.

Building Biotechnology enables business professionals and entrepreneurial scientists to understand the biotechnology industry, its drivers, and opportunities and strategies for commercial success.

The Biotech Investor: How to Profit from the Coming Boom in Biotechnology
by Tom Abate

The world is entering a biotechnology boom but only informed investors will prosper in the incredibly complex biotech business. Separating the bioengineered wheat from the chaff, this book gives investors the analytical foundation to understand the science, finances, time horizon and technological and commercial potential.

In'The Biotech Investor' San Francisco Chronicle biotechnology reporter Tom Abate explains the science, finances, time horizon, and technological and commercial potential of this burgeoning industry.

Abate provides guidelines for assessing company leadership, easy-to-digest reports from the labs, and indispensable investor tools and metrics.

Building Global Biobrands : Taking Biotechnology to Market
by Francoise Simon (Foreword), Philip Kotler

From medicine and defense to food and cosmetics, biotechnological breakthroughs are creating huge new global market opportunities as well as unprecedented challenges. Companies from mega-pharmaceuticals to infotech giants and biotech start-ups must radically rethink their business models. In the first book on the business of biotechnology, Françoise Simon and Philip Kotler combine their biotechnology and marketing ex-pertise to show managers how to innovate with bionetworks, win customers with biobrands, and create sustainable advantage worldwide.

Simon and Kotler explain in clear nontechnical prose how innovation in the new biosector will be driven by a web of cross-industry collaborations, and in particular by three transforming forces: information technology, consumerism, and systems biology. With timely industry cases, the authors demonstrate that by capitalizing on these forces, companies from Hitachi and Siemens to Amgen and Pfizer could become the biotech leaders of the coming decades.

The chapters on building and sustaining biobrands are the centerpiece of this indispensable book. Simon and Kotler present a powerful framework that will enable any manager to redefine and transform traditional models into a new branding paradigm: the global "targeted" model as an alternative to the global "mass market" model. The authors illustrate how each of these models has proven successful in launching such blockbuster drugs as Viagra, Lipitor, Rituxan, and Gleevec.

Relevant to all industries impacted by biotechnology from consumer goods to industrial products, Building Global Biobrands is essential reading for every manager, marketer, analyst, and consultant who must understand the Biotech Century.

Rights And Liberties In The Biotech Age
by Bill McKibben (Foreword), Paul R. Billings (Afterword), Sheldon Krimsky (Editor), Peter Shorett

Rights and Liberties in the Biotech Age is the first book reaching broadly into biotechnology that imbeds the issues into a rights framework for the social management of technology. The contributors to the volume comprise prominent university scientists, civil rights lawyers, and public interest activists who bring their perspectives to issues where science and civil liberties meet head on. This book explores the impact of new genetic technologies on how people define their "personhood" and their basic civil liberties. It questions the thesis of "scientism" where "rights" must adapt and conform to technological changes. Instead, the authors explore the expansion of human rights in the face of new biomedical and bio-agricultural advances so that "rights" and not "technologies" are at the forefront of discussion.

Recommend books, please contact:

You can find resources related to this topic in
the sections about

Club of Amsterdam Journal
Club of Amsterdam blog
by name

and for more events


Copyright © 2002-2018 Club of Amsterdam. All rights reserved.    Contact     Privacy statement    Cancellation Policy